Breast NeoplasmsMastectomyNerve BlockDexmedetomidinePain, PostoperativeChronic PainPrognosis
Investigational drug(s) / intervention(s)
Erector spinae plane blockControl group
Erector spinae plane block: Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
Control group: General anesthesia alone.
Study summary
Chronic postsurgical pain (CPSP) has an incidence of 46% in patients after breast cancer surgery, which seriously affects patients' physiological and psychological function, as well as quality of life. Acute pain is an independent risk factor for persistent pain after surgery. Erector spinae plane block (ESPB) provided excellent perioperative analgesia in patients undergoing breast surgery. Dexmedetomidine as an adjuvant of local anesthetics prolongs the duration of peripheral nerve block and decreases the requirements of postoperative analgesia. The investigators hypothesize that, for breast cancer patients undergoing mastectomy, ESPB (with a combination of 0.5% ropivacaine 35 ml and dexmedetomidine 1 microgram/kg) can reduce the occurrence of CPSP. The purpose of this randomized controlled trial is to investigate the impact of ESPB with adjuvant dexmedetomidine on the incidence of CPSP in breast cancer patients after mastectomy. We will also observe the impact of ESPB on long-term survival in these patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age of 18 years or over, but less than 85 years;
2. Scheduled to undergo mastectomy for primary unilateral breast cancer.
Exclusion Criteria:
1. Previous breast cancer surgery with an incision of \>2 cm;
2. Chronic opioid dependence or long-term intake of analgesic medicines (\>3 months);
3. Any contraindication to erector spinae plane block, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy;
4. Inability to communicate in the preoperative period because of profound dementia, deafness, language barriers, or end-stage disease;
5. History of malignant tumor in other organs, or a current combination of malignant tumor of other organs;
6. History of coronary heart disease (diagnosed coronary stenosis, previous myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass grafting); preoperative hepatic or renal impairment (alanine transaminase and/or aspartate transaminase ≥2 times of upper limit of normal, or serum creatinine\>133 µmol/L); history of peptic ulcer or hemorrhage; ASA classification IV or above;
7. Allergy to ropivacaine.
Primary outcome measure(s)
Incidence of chronic postsurgical pain (CPSP) at 6 months after surgery — At 6 months after surgery CPSP is defined as pain persisting for at least three months after surgery that was not present before surgery or that had different characteristics, and other possible causes of pain were excluded (e.g., cancer recurrence, infection).
Progression-free survival (long-term outcomes) — Up to 3 years after surgery Progression-free survival is defined as the time from randomization to disease progression (recurrence or metastasis) or death from any cause.
Trial sites (2)
Facility
City
Region
Status
Peking University First Hospital
Beijing
Beijing Municipality
Recruiting
Beijing Cancer Hospital
Beijing
Beijing Municipality
Recruiting
More Peking University First Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.